• Pau Llàcer, Julio Núñez, Luis Manzano, José María Cepeda Rodrigo, Prado Salamanca Bautista, Marcos Guzmán García, Joan Carles Trullás Vila, Raúl Quirós López, Manuel Lorenzo López Reboiro, Manuel Montero-Pérez-Barquero, and en representación de los investigadores del registro Rica.
• Servicio de Medicina Interna, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, España. Electronic address: paullacer@hotmail.com.
• Med Clin (Barc). 2022 Aug 26; 159 (4): 164-170.

BackgroundCarbohydrate antigen 125 (CA125) has emerged as a new biomarker in heart failure. The objective of the study is to determine whether serum CA125 levels predict total mortality and readmissions at one year in patients >70 years old with acute heart failure (AHF) and preserved ejection fraction (PEF).MethodsMulticenter prospective observational study, which included 359 patients (mean age 81.5 years). The primary endpoint was total all-cause mortality and total readmissions for AHF at 1 year. A negative binomial regression technique was used to evaluate the association between CA125 and both endpoints.ResultsAt one year of follow-up, 87 deaths (24.2%) were registered. The patients in the lower quartile of CA125 had a lower crude mortality rate (14.4%, 26.7, 26.7, 29.2; p=0.09). After multivariate analysis, the CA125 value was positively associated with a higher risk (p=0.009). Such association was also positive but borderline significant for the risk of readmissions (p=0.089).ConclusionsIn a population older than 70 years hospitalized for AHF with PEF, elevated levels of CA125 are associated with an increased risk of death at one year of follow-up. The association with readmission for AHF was more uncertain. Low levels of CA125 identifies a subgroup at low-risk.Copyright © 2021 Elsevier España, S.L.U. All rights reserved.

19 keywords...

hide…